top of page

Sonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it.

Oct 29, 2025
1 min read

They explain why they believe a Treg based cell therapy is the right approach for autoimmune conditions, and describe the construct of this particular product. After discussing the data, they also comment on what they believe the big picture is for these types of Treg based treatments going forward.

https://vimeo.com/1131809918

Recent Posts

Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads

Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads

Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month

Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month

San Diego based Replicate Bioscience believes that self-replicating RNA (srRNA) has key advantages over linear or circular RNA. Last year Novo signed on as a partner in obesity and diabetes

San Diego based Replicate Bioscience believes that self-replicating RNA (srRNA) has key advantages over linear or circular RNA. Last year Novo signed on as a partner in obesity and diabetes

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page